Physician profile

Jeffrey C King

Hand Surgery · Kalamazoo, MI

NPI 1003850686

$3,048.56

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$518.51

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medwest Associates $1,231.03 2022-2023
Skeletal Dynamics INC $572.26 2019
Trice Medical, INC. $465.73 2019-2023
Acumed LLC $225.24 2020-2022
Trimed, INC. $211.11 2019-2023
Checkpoint Surgical, INC $107.63 2019
Depuy Synthes Sales INC. $104.94 2024 Velys
Arthrosurface Incorporated $76.99 2019
Stryker Corporation $53.63 2024 Conextions Tr Tendon Repair System-Implant Mechanism, Latitude Ev

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jeffrey C King

$3,048.56

in general payments reported 2019-2025

Years
2019-2024
Top company
Medwest Associates

https://glasscript.com/doctor/45454/jeffrey-c-king

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.